Cannabinoid Research

Biotech Companies Investing Millions of Dollars in the Medical Marijuana Market to Develop Cannabinoid Products

Frost & Sullivan's recent analysis on medical cannabis finds that the total revenue of this market in the United States is expected to grow from $5.32 billion in 2017 to $10 billion in 2022, at a compound annual growth rate (CAGR) of 13.6%. Even though the Food and Drug Administration (FDA) has approved only a few medical marijuana-derived products, there will be a strong growth trajectory over the next few
Biotechnology cancer Cannabinoid Research

Study finds up to one-quarter of cancer patients use marijuana

A new study conducted in a cancer center in a state with legalized medicinal and recreational marijuana found that approximately one-quarter of surveyed patients used marijuana in the past year, mostly for physical and psychological symptoms. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that legalization also revealed that legalization increased the likelihood for use among patients. Eight states and the
Antibiotics Cannabinoid Research Infectious Diseases Prodrug

New Arsenal Against MRSA: New Study Reports Cannabinoids Effective Against Antibiotic-Resistant MRSA

Researchers have found that cannabinoid-based therapies have unique anti-bacterial properties that fight MSRA and other infectious bacteria. In vitro studies demonstrated that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and mupirocin-resistant (MR-MRSA) strains of MRSA. Researchers also found that using unique strategic cannabinoid-based cocktails, fractional-inhibitory concentration (FIC) levels demonstrating synergy between
Cannabinoid Research Ophthalmology

Cannabinoid-Based Therapeutics may present opportunity in Reducing Intraocular Pressure: Study

Data from a preclinical study presented last week at the 2016 AAPS National Meeting demonstrated significant data concerning the effects of a cannabinoid-based drug in lowering the effect of Intraocular Pressure (IOP). The abstract, "Effect of single versus multiple day regimen of Δ9 -THC-valine-hemisuccinate (THCVHS) on the intra-ocular pressure (IOP) lowering activity in normotensive rabbits" (abstract # 30W0830), reports data comparing the prodrug of tetrahydrocannabinol (THCVHS) also known as NB1111 (Nemus
Cannabinoid Research Ophthalmology Pharmaceuticals

New Class of Medicinals based on Cannabinoid Molecules, Spurs NEMUS Bioscience Inc. into Action

Q&A with Brian Murphy MD, CEO/CMO, NEMUS Bioscience Humans produce a range of chemical compounds called cannabinoids that keep the human body stable by binding to receptors on cell membranes and controlling the release of chemical messengers that regulate everything from how humans experience pain to our moods. While most people's endocannabinoid systems naturally help maintain a state of homeostasis, or stability, conditions such as multiple sclerosis or treatments for